Information

Related Research Units

Infectious Diseases Research

Research Overview

Mari M. Nakamura, MD, MPH, is a pediatric infectious diseases physician and health services researcher. Her work focuses on improving infectious diseases care for children by optimizing antibiotic use through antimicrobial and diagnostic stewardship, quality improvement, and the use of information technology. She is also deeply interested in medical education and serves as a research mentor for clinical fellows and faculty interested in antimicrobial stewardship.

Research Background

Dr. Nakamura received her MD from Washington University School of Medicine in 1999.  She completed pediatric residency training at Vanderbilt Children’s Hospital in 2002 and pediatric infectious diseases fellowship training at Lucile Packard Children’s Hospital at Stanford in 2006.  She came to Boston Children’s Hospital in 2006 to join the Harvard Pediatric Health Services Research Fellowship Program and became a faculty member in 2009.  She received an MPH from the Harvard School of Public Health in 2008. 

 

Education

Medical School

Washington University School of Medicine
1999 St. Louis MO

Internship

Vanderbilt Children's Hospital
2000 Nashville TN

Residency

Vanderbilt Children's Hospital
2002 Nashville TN

Fellowship

Pediatric Infectious Diseases Lucile Packard Children's Hospital, Stanford University
2006 Stanford CA

Fellowship

Pediatric Health Services Research Boston Children’s Hospital and Department of Population Medicine, Harvard Medical School
2009 Boston MA

Graduate School

MPH Harvard School of Public Health
2008 Boston MA

Publications

  1. Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis. J Pediatric Infect Dis Soc. 2024 Jul 20; 13(7):352-362. View Abstract
  2. Emergency Department Antibiotic Prescribing for Pediatric Urinary Tract Infections, 2011-2020. Pediatrics. 2024 Jul 01; 154(1). View Abstract
  3. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022). Clin Infect Dis. 2024 Jun 27; 78(7):e250-e349. View Abstract
  4. Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce. J Pediatric Infect Dis Soc. 2024 Mar 19; 13(3):159-185. View Abstract
  5. Implementation and Perceived Effectiveness of Prospective Audit and Feedback and Preauthorization by US Pediatric Antimicrobial Stewardship Programs. J Pediatric Infect Dis Soc. 2024 Feb 26; 13(2):117-122. View Abstract
  6. An Algorithm to Assess Guideline Concordance of Antibiotic Choice in Community-Acquired Pneumonia. Hosp Pediatr. 2024 02 01; 14(2):137-145. View Abstract
  7. Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis. medRxiv. 2024 Jan 18. View Abstract
  8. Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study. J Pediatric Infect Dis Soc. 2023 Apr 18; 12(3):152-155. View Abstract
  9. Digital Antimicrobial Stewardship Decision Support to Improve Antimicrobial Management. Appl Clin Inform. 2023 05; 14(3):418-427. View Abstract
  10. Community-Onset Bacterial Coinfection in Children Critically Ill With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infect Dis. 2023 Mar; 10(3):ofad122. View Abstract
  11. Impact of a Documented Penicillin Allergy on Antibiotic Selection in Pediatric Patients With Osteomyelitis. Pediatr Infect Dis J. 2023 05 01; 42(5):e140-e142. View Abstract
  12. Life-Threatening Complications of Influenza vs Coronavirus Disease 2019 (COVID-19) in US Children. Clin Infect Dis. 2023 02 08; 76(3):e280-e290. View Abstract
  13. Simultaneous Late, Late-Onset Group B Streptococcal Meningitis in Identical Twins. Clin Pediatr (Phila). 2023 02; 62(2):96-99. View Abstract
  14. Epidemiology and Management of Orbital Cellulitis in Children. J Pediatric Infect Dis Soc. 2022 May 30; 11(5):214-220. View Abstract
  15. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. J Pediatric Infect Dis Soc. 2022 May 30; 11(5):177-185. View Abstract
  16. Immunisation rates and predictors of undervaccination in infants with CHD. Cardiol Young. 2023 Feb; 33(2):242-247. View Abstract
  17. Utility of Broad-Range PCR Sequencing for Infectious Diseases Clinical Decision Making: a Pediatric Center Experience. J Clin Microbiol. 2022 05 18; 60(5):e0243721. View Abstract
  18. Epidemiology and outcomes of invasive aspergillosis among pediatric immunocompromised patients: A 12-year single-center experience. Med Mycol. 2022 Mar 12; 60(4). View Abstract
  19. Comorbidities Associated with Hospitalization and Progression Among Adolescents with Symptomatic Coronavirus Disease 2019. J Pediatr. 2022 06; 245:102-110.e2. View Abstract
  20. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. J Pediatric Infect Dis Soc. 2021 May 28; 10(5):629-634. View Abstract
  21. Variability in Ceftriaxone Dosing Across 32 US Acute Care Children's Hospitals. J Pediatric Infect Dis Soc. 2021 May 28; 10(5):677-681. View Abstract
  22. Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. J Pediatric Infect Dis Soc. 2021 Feb 13; 10(1):34-48. View Abstract
  23. Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. J Pediatric Infect Dis Soc. 2020 Dec 31; 9(6):701-715. View Abstract
  24. Encouraging Entrustment: A Qualitative Study of Resident Behaviors That Promote Entrustment. Acad Med. 2020 11; 95(11):1718-1725. View Abstract
  25. A Call for Pediatric COVID-19 Clinical Trials. Pediatrics. 2020 08; 146(2). View Abstract
  26. Potential Impact of Initial Clinical Data on Adjustment of Pediatric Readmission Rates. Acad Pediatr. 2019 07; 19(5):589-598. View Abstract
  27. Safety and Tolerability of Moxifloxacin in Children. J Pediatric Infect Dis Soc. 2018 Aug 17; 7(3):e92-e101. View Abstract
  28. Safety of Outpatient Parenteral Antimicrobial Therapy in Children. Pediatr Infect Dis J. 2018 02; 37(2):157-163. View Abstract
  29. Readmission After Pediatric Mental Health Admissions. Pediatrics. 2017 Dec; 140(6). View Abstract
  30. Pediatric Readmissions After Hospitalizations for Lower Respiratory Infections. Pediatrics. 2017 Aug; 140(2). View Abstract
  31. Same-Hospital Readmission Rates as a Measure of Pediatric Quality of Care. JAMA Pediatr. 2015 Oct; 169(10):905-12. View Abstract
  32. Factors associated with meaningful use incentives in children's hospitals. Pediatrics. 2015 Jun; 135(6):e1409-16. View Abstract
  33. Impact of the meaningful use incentive program on electronic health record adoption by US children's hospitals. J Am Med Inform Assoc. 2015 Mar; 22(2):390-8. View Abstract
  34. Measuring pediatric hospital readmission rates to drive quality improvement. Acad Pediatr. 2014 Sep-Oct; 14(5 Suppl):S39-46. View Abstract
  35. Using Medicaid and CHIP claims data to support pediatric quality measurement: lessons from 3 centers of excellence in measure development. Acad Pediatr. 2014 Sep-Oct; 14(5 Suppl):S76-81. View Abstract
  36. Trainee and program director perceptions of quality improvement and patient safety education: preparing for the next accreditation system. Clin Pediatr (Phila). 2014 Nov; 53(13):1248-54. View Abstract
  37. Change in adoption of electronic health records by US children's hospitals. Pediatrics. 2013 May; 131(5):e1563-75. View Abstract
  38. Pediatric readmission prevalence and variability across hospitals. JAMA. 2013 Jan 23; 309(4):372-80. View Abstract
  39. Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. Int Health. 2011 Dec; 3(4):270-81. View Abstract
  40. Cost effectiveness of child pneumococcal conjugate vaccination in GAVI-eligible countries. Int Health. 2011 Dec; 3(4):259-69. View Abstract
  41. Electronic health record adoption by children's hospitals in the United States. Arch Pediatr Adolesc Med. 2010 Dec; 164(12):1145-51. View Abstract
  42. Higher prevalence of pharyngeal than nasal Staphylococcus aureus carriage in pediatric intensive care units. J Clin Microbiol. 2010 Aug; 48(8):2957-9. View Abstract
  43. Influenza vaccination in adolescents with high-risk conditions. Pediatrics. 2008 Nov; 122(5):920-8. View Abstract
  44. Pharyngeal carriage of Staphylococcus aureus in pediatric intensive care units. Poster presentation at the Children's Hospital Boston Infectious Diseases Division Research Retreat,. 2008. View Abstract
  45. Service-oriented architecture for pediatric immunization decision support. Poster presentation at the American Medical Informatics Association Annual Meeting,. 2007. View Abstract
  46. Service-oriented architecture for pediatric immunization decision support. AMIA Annu Symp Proc. 2007 Oct 11; 1056. View Abstract
  47. Influenza vaccination in adolescents with high-risk conditions. Poster presentation at the Infectious Diseases Society of America Annual Meeting,. 2007. View Abstract
  48. Influenza vaccination in adolescents with high-risk conditions. Podium presentation at the Annual NRSA Research Trainees Conference,. 2007. View Abstract
  49. Growth phase- and nutrient limitation-associated transcript abundance regulation in Bordetella pertussis. Infect Immun. 2006 Oct; 74(10):5537-48. View Abstract
  50. Targeting a complex transcriptome: the construction of the mouse full-length cDNA encyclopedia. Genome Res. 2003 Jun; 13(6B):1273-89. View Abstract
  51. Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage in the community pediatric population. Pediatr Infect Dis J. 2002 Oct; 21(10):917-22. View Abstract

Contact Mari Nakamura

Print Profile